TGF-beta 3

TGF-beta 3 Molekülinformation

Englischer Name	Transforming growth factor beta 3	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3	Target-Alias	Transforming Growth Factor beta3，TGFB3，LAP，Prepro-Transforming Growth Factor Beta-3，TGF-Beta3，Transforming Growth Factor， Beta 3，ARVD1，LDS5，Arrhythmogenic Right Ventricular Dysplasia 1，RNHF，Transforming growth factor beta-3 proprotein，ARVD
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Transforming growth factor beta 3
Target-Alias	Transforming Growth Factor beta3，TGFB3，LAP，Prepro-Transforming Growth Factor Beta-3，TGF-Beta3，Transforming Growth Factor， Beta 3，ARVD1，LDS5，Arrhythmogenic Right Ventricular Dysplasia 1，RNHF，Transforming growth factor beta-3 proprotein，ARVD
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

TGF-beta 3 Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (3)
Etikett
Tag Free (1)His Tag & Avi Tag (1)His Tag (1)
Marker
Unconjugated (2)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
TG3-H5213	Human	HEK293	Human TGF-beta 3 / TGFB3 Protein, premium grade	In den Warenkorb legen
TG3-H52H5	Human	HEK293	Human Latent TGF-beta 3 / Latent TGFB3 Protein, His Tag	In den Warenkorb legen
TG3-H82E6	Human	HEK293	Biotinylated Human Latent TGF-beta 3 / Latent TGFB3 Protein, His,Avitag™	In den Warenkorb legen

Gesamtmenge3

TGF-beta 3 Molekülhintergrund

Transforming growth factor beta 3 ( TGFB3) is also known as TGF-β3, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development. TGF-beta 3 is similar with TGF-beta 1 and -beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial-mesenchymal transition. TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.

TGF-beta 3 Molekülalias

TGFB3,ARVD,TGF-beta3

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Dalutrafusp alfa	GS-1423; AGEN-1423	Phase 2 Clinical	Agenus Inc	Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
RG-6315	RG-6315	Phase 1 Clinical	Genentech Inc	Scleroderma, Systemic	Details
BMS-986416	BMS-986416; AVID-200 DP; AVID-200	Phase 1 Clinical	Formation Biologics Corp	Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Solid tumours; Thrombocythemia, Essential	Details